A study on usefulness and safety of donepezil for cognitive function and phychological symptoms of patients with Parkinson's disease and Alzheimer type dementia.
Phase of Trial: Phase II
Latest Information Update: 26 May 2017
Price : $35 *
At a glance
- Drugs Donepezil (Primary)
- Indications Alzheimer's disease; Parkinson's disease
- Focus Therapeutic Use
- 21 May 2017 Status changed from recruiting to discontinued.
- 17 Dec 2013 Planned number of patients changed from 20 to 50 as reported by University Hospital Medical Information Network - Japan.
- 22 May 2013 New trial record